So did either one of you take the time to research NAN when I mentioned it (before it went from $1.15 to $1.49??
Printable View
Well, I thought its time I finally joined the fun. Two days ago, I was researching internet forums for bladder cancer to see what I could find. Anyway, found details of an Israeli company wanting to take a slice of the pie.
http://money.cnn.com/news/newsfeeds/...re/IN21558.htm
The CellDetect® urine test successfully identified cancerous cells in urine samples in patients with a history of the disease, with reported sensitivity of 84.4% and specificity of 82.7% for the study's primary endpoint.
So, I certainly hope the PEB horse has enough lead to win the race.
It seems to be more of a test for recurrance primarily, rather than an early stage diagnostic test or a perhaps prognostic test. It would be interesting actually to see what the sensitivity and specificity specs are for Tis, Ta, T1, T2 and T3 stages, which seem to be much harder to achieve with the sort of results Cxbladder(detect) achieves.
Might be a competitor for Cxbladder(health) though when launched though sometime down stream, suspect that they may have to do more than just a 217 patient trial though.
Nothing tells us more about how hopelessly compromised paid research is - S&P effectively paying a US$1.375 billion fine to settle the case against it for the bastardization of its research and ratings.
So take Edison's research paid for the company with the above in mind.